Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jun;10(2):142-51.
doi: 10.1007/s11904-013-0157-9.

Use of antiretrovirals for HIV prevention: what do we know and what don't we know?

Jared M Baeten  1 , Robert Grant
Affiliations
Review

Use of antiretrovirals for HIV prevention: what do we know and what don't we know?

Jared M Baeten et al. Curr HIV/AIDS Rep. 2013 Jun.

Abstract

Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered--including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of "next-generation" PrEP agents to improve on this effective technology.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest:

Jared Baeten declares that he has no conflict of interest.

Robert Grant declares that he has no conflict of interest.

References

    1. Cohen MS, Gay C, Kashuba AD, Blower S, Paxton L. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Annals of Internal Medicine. 2007;146:591–601. - PubMed
    1. Baeten J, Celum C. Systemic and topical drugs for the prevention of HIV infection: antiretroviral pre-exposure prophylaxis. Annual Review of Medicine. 2012;27:27. - PMC - PubMed
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine. 2011;365:493–505. This randomized clinical trial provided definitive evidence that use of antiretroviral treatment by HIV-infected persons reduces the risk of HIV transmission to sexual partner. Use of antiretroviral medications for treatment of HIV infected persons to reduce infectiousness and PrEP for HIV uninfected persons to reduce susceptibility are complementary prevention strategies. - PMC - PubMed
    1. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092–8. - PMC - PubMed
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine. 2012;367:399–410. This randomized clinical trial demonstrated that oral PrEP, using daily oral FTC/TDF and daily oral TDF alone, was efficacious for prevention of HIV acquisition in both heterosexual men and women who were in HIV serodiscordant partnerships. - PMC - PubMed

Publication types